Background: A significant proportion of ischemic strokes are cryptogenic. In this context, the clinical pertinence of patent foramen ovale (PFO) with and without atrial septum aneurysm (ASA) remains controversial. The aim of this study was to identify how PFO +/–ASA and cryptogenic stroke are associated in a representative sample of stroke patients. Methods: We enrolled all patients (n = 909) with ischemic stroke or transient ischemic attack admitted to the certified stroke unit or neurological intensive care unit of our university medical center who underwent transesophageal echocardiography (TEE) between 2012 and 2014. The baseline characteristics, cardio-/neurovascular risk factors, clinical parameters and TEE findings were analyzed. Results: PFO was present in 26.2%, and PFO was combined with an ASA in 9.9%. In cryptogenic stroke, the prevalence of PFO was higher compared to other etiologies (30.9 vs. 21.9%; p < 0.002). Patients with PFO had lower National Institute of Health Stroke Score (NIHSS) values at admission than those without (2 [0–5] vs. 3 [1–7]; p = 0.001; 95% CI [0.62–0.88]). No difference was found in NIHSS values of PFO patients with or without ASA (2 [0–5] vs. 2 [0–5]; p = 0.683; 95% CI 0.94 [0.68–1.28]). Conclusions: Our study indicates that a detected PFO +/–ASA could exhibit a stroke-relevant finding, if classical risk factors for the stroke were lacking.

Keywords:
Ischemic stroke, Patent foramen ovale, Echocardiography
1.
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O&apos;Donnell MJ, Sacco RL: Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429–438.
2.
Handke M, Harloff A, Olschewski M, Hetzel A, Geibel: Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007; 357: 2262–2268.
3.
Alsheikh-Ali AA, Thaler DE, Kent DM: Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009; 40: 2349–2355.
4.
Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172–1179.
5.
Kent DM, Thaler DE: Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke 2010; 41:S26–S30.
6.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160–236.
7.
Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators: Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092–1100.
8.
Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L: Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991–999.
9.
Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Jüni P: Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083–1091.
10.
Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Saver JL, Smalling RW, Jüni P, Mattle HP, Meier B, Thaler DE: Device closure of patent foramen ovale after stroke pooled analysis of completed randomized trials. J Am Coll Cardiol 2016 ;67: 907–917.
11.
Consoli D, Paciaroni M, Galati F, Aguggia M, Melis M, Malferrari G, Consoli A, Vidale S, Bosco D, Cerrato P, Sacco S, Gandolfo C, Bovi P, Serrati C, Del Sette M, Cavallini A, Diomedi M, Postorino P, Reboldi P, Ricci S; behalf of SISIFO group: Prevalence of patent foramen ovale in ischaemic stroke in Italy: results of SISIFO study. Cerebrovasc Dis 2015; 39: 162–169.
12.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gorden DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
13.
Musolino R, La Spina P, Granata A, Gallitto G, Leggiadro N, Carerj S, Manganaro A, Tripodi F, Epifanio A, Gangemi S, Di Perri R: Ischaemic stroke in young people: a prospective and long-term follow-up study. Cerebrovasc Dis. 2003; 15: 121–128.
14.
Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P: Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke. 2000; 31: 398–403.
15.
Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, Lyrer PA, Engelter ST: Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. Stroke 2006; 37: 2030–2034.
16.
Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, Diener HC, Di Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar MD: Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology 2016; 86: 261–269.
17.
Mas JL, Arquizan C, Lamy C, Zuber M, Cabanas L, Derumeaux G, Coste J; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740–1746.
18.
Homma S, Sacco RL, Di Tullio MR, Sciatica RR, Mohr JP: Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–2631.
19.
Sun YP, Homma S: Patent foramen ovale and stroke. Circ J 2016; 80: 1665–1673.
20.
Jung JM, Lee JY, Kim HJ, Do Y, Kwon SU, Kim JS, Song JK, Kang DW: Patent foramen ovale and infarct volume in cryptogenic stroke. J Stroke Cerebrovasc Dis 2013; 22: 1399–1404.
21.
Wessler BS, Thaler DE, Ruthazer R, Weimar C, Di Tullio MR, Elkind MS, Homma S, Lutz JS, Mas J, Mattle HP, Meier B, Nedeltchev K, Papetti F, Di Angelantonio E, Reisman M, Serena J, Kent DM: Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging 2014; 7: 125–131.
22.
Rigatelli G, Dell’Avvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S, Chinaglia M, Mandapaka S, Kuruvilla J, Chen JP, Nanjundappa A: Permanent right-to-left shunt is the key factor in managing patent foramen ovale. J Am Coll Cardiol 2011; 58: 2257–2261.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.